-
Ultimovacs ASA – Private placement of new shares successfully placed
-
Ultimovacs ASA – Private placement of new shares successfully placed
-
Ultimovacs ASA – Contemplated private placement
-
Ultimovacs to Launch Phase II Combination Trial of UV1 in Lung Cancer (NSCLC)
-
Ultimovacs Receives Dual FDA Fast Track Designation for UV1 in Advanced Malignant Melanoma
-
Ultimovacs ASA: New share capital registered
-
Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma
-
Ultimovacs ASA: Share capital increase related to exercise of options
-
Ultimovacs ASA announces Two Key Appointments to the Management Team as the Operations Advances
-
Ultimovacs Begins Dosing of Second Cohort in Phase I TENDU Study Investigating Prostate Cancer-Specific Therapeutic Vaccine
